科霸生物

CureBay Biopharmaceuticals is a clinical-stage biotechnology company based in Suzhou, China, dedicated to developing next-generation cytokine immunotherapies for cancer. The company utilizes its proprietary Smart-CK (Smart Cytokine) platform to engineer cytokines that remain inactive in systemic circulation and are specifically activated by proteases within the tumor microenvironment. This approach is designed to overcome the historical challenges of cytokine therapy, such as severe systemic toxicity and a narrow therapeutic window, by concentrating activity at the disease site. Their lead program, CB001, is an optimized Interleukin-2 (IL-2) prodrug currently undergoing clinical evaluation for the treatment of solid tumors. CureBay is led by a management team with extensive experience in global drug development and is backed by prominent life science investors.